Skip to main content
SpringerLink
Log in

Allelic variation in the serotonin transporter promoter affects neuromodulatory effects of a selective serotonin transporter reuptake inhibitor (SSRI)

  • Original Investigation
  • Published:
Psychopharmacology Aims and scope Submit manuscript

Abstract

Rationale

Antidepressant efficacy of selective serotonin reuptake inhibitors (SSRIs) has been shown to depend on functional polymorphisms within the promoter region of the serotonin transporter gene (5-HTTLPR). This gene gives rise to a biallelic polymorphism designated long (l) and short (s). Homozygosity for the long variant (ll-genotype) is associated with a two times more efficient 5-HT uptake compared to the s/l- or s/s-genotype. Paired pulse transcranial magnetic stimulation is a feasible tool in detecting changes of motor cortex excitability induced by SSRIs.

Objective

Our study aimed to measure neuromodulatory effects of SSRIs on cortical excitability in healthy volunteers characterized by distinct genotypes of the 5-HTTLPR.

Methods

Cortical excitability was determined in eight genetically defined subjects pre- and post-ingestion of 60 mg citalopram.

Results

Subjects with the ll-genotype of the 5-HTTLPR showed a significant enhancement of a particular component of motor cortex excitability (intracortical inhibition) as compared to volunteers without the ll-genotype.

Conclusion

Distinct neuromodulatory effects after intake of citalopram based on allelic variations of the 5-HTTLPR may explain variable response of patients treated with SSRIs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1.

Similar content being viewed by others

References

  • Benkert O, Hippius H (1998) Kompendium der Psychiatrischen Pharmakotherapie. Springer, Berlin Heidelberg

  • Bolden-Watson C, Richelson E (1993) Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sci 52:1023–1029

    CAS  PubMed  Google Scholar 

  • Carboni E, Tanda GL, Frau R, Di Chiara G (1990) Blockade of the noradrenaline carrier increases extracellular dopamine concentrations in the prefrontal cortex: evidence that dopamine is taken up in vivo by noradrenergic terminals. J Neurochem 55:1067–1070

    CAS  PubMed  Google Scholar 

  • Gingrich JA, Hen R (2001) Dissecting the role of the serotonin system in neuropsychiatric disorders using knockout mice. Psychopharmacology 155:1–10

    Article  CAS  PubMed  Google Scholar 

  • Golembiowska K, Dziubina A (2000) Effect of acute and chronic administration of citalopram on glutamate and aspartate release in the rat prefrontal cortex. Pol J Pharmacol 52:441–448

    CAS  PubMed  Google Scholar 

  • Goodnick PJ, Goldstein BJ (1998) Selective serotonin reuptake inhibitors in affective disorders. I. Basic pharmacology. J Psychopharmacol 12:S5–20

    CAS  PubMed  Google Scholar 

  • Heils A, Teufel A, Petri S, Stober G, Riederer P, Bengel D, Lesch KP (1996) Allelic variation of human serotonin transporter gene expression. J Neurochem 66:2621–2624

    CAS  PubMed  Google Scholar 

  • Ilic TV, Korchounov A, Ziemann U (2002) Complex modulation of human motor cortex excitability by the specific serotonin re-uptake inhibitor sertraline. Neurosci Lett 319:116–120

    CAS  PubMed  Google Scholar 

  • Jansen KL, Faull RL, Dragunow M, Leslie RA (1991) Distribution of excitatory and inhibitory amino acid, sigma, monoamine, catecholamine, acetylcholine, opioid, neurotensin, substance P, adenosine and neuropeptide Y receptors in human motor and somatosensory cortex. Brain Res 566:225–238

    CAS  Google Scholar 

  • Joubert AF, Sanchez C, Larsen F (2000) Citalopram. Hum Psychopharmacol Clin Exp 15:439–451

    Article  CAS  Google Scholar 

  • Lesch KP, Bengel D, Heils A, Sabol SZ, Greenberg BD, Petri S, Benjamin J, Muller CR, Hamer DH, Murphy DL (1996) Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 274:1527–1531

    CAS  PubMed  Google Scholar 

  • Liepert J, Schardt S, Weiller C (2001) Orally administered atropine enhances motor cortex excitability: a transcranial magnetic stimulation study in human subjects. Neurosci Lett 300:149–152

    Article  CAS  PubMed  Google Scholar 

  • McLaughlin DP, Little KY, Lopez JF, Watson SJ (1996) Expression of serotonin transporter mRNA in human brainstem raphe nuclei. Neuropsychopharmacology 15:523–529

    Article  CAS  PubMed  Google Scholar 

  • Maeda F, Gangitano M, Thall M, Pascual-Leone A (2002) Inter- and intra-individual variability of paired-pulse curves with transcranial magnetic stimulation (TMS). Clin Neurophysiol 113:376–382

    PubMed  Google Scholar 

  • Pollock BG, Ferrell RE, Mulsant BH, Mazumdar S, Miller M, Sweet RA, Davis S, Kirshner MA, Houck PR, Stack JA, Reynolds CF, Kupfer DJ (2000) Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology 23:587–590

    Article  CAS  PubMed  Google Scholar 

  • Price CJ, Pittman QJ (2001) Dopamine D4 receptor activation inhibits presynaptically glutamatergic neurotransmission in the rat supraoptic nucleus. J Neurophysiol 86:1149–1155

    CAS  PubMed  Google Scholar 

  • Rossini PM, Barker AT, Berardelli A, Caramia MD, Caruso G, Cracco RQ, Dimitrijevic MR, Hallett M, Katayama Y, Lucking CH et al. (1994) Non-invasive electrical and magnetic stimulation of the brain, spinal cord and roots: basic principles and procedures for routine clinical application. Report of an IFCN committee. Electroencephalogr Clin Neurophysiol 91:79–92

    CAS  PubMed  Google Scholar 

  • Schwenkreis P, Liepert J, Witscher K, Fischer W, Weiller C, Malin JP, Tegenthoff M (2000) Riluzole suppresses motor cortex facilitation in correlation to its plasma level. A study using transcranial magnetic stimulation. Exp Brain Res 135:293–299

    CAS  PubMed  Google Scholar 

  • Smeraldi E, Zanardi R, Benedetti F, Di Bella D, Perez J, Catalano M (1998) Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol Psychiatry 3:508–511

    CAS  PubMed  Google Scholar 

  • Sommer M, Wu T, Tergau F, Paulus W (2002) Intra- and interindividual variability of motor responses to repetitive transcranial magnetic stimulation. Clin Neurophysiol 113:265–269

    Article  CAS  PubMed  Google Scholar 

  • Stahl SM (2000) Essential psychopharmacology of depression and bipolar disorder. Cambridge University Press, Cambridge

  • Tan JY, Levin GM (1999) Citalopram in the treatment of depression and other potential uses in psychiatry. Pharmacotherapy 19:675–689

    CAS  PubMed  Google Scholar 

  • Van Woert MH, Rosenbaum D, Chung EY (1986) Biochemistry and therapeutics of posthypoxic myoclonus. Adv Neurol 43:171–181

    PubMed  Google Scholar 

  • Wassermann EM (2002) Variation in the response to transcranial magnetic brain stimulation in the general population. Clin Neurophysiol 113:1165–1171

    Article  PubMed  Google Scholar 

  • Werhahn KJ, Forderreuther S, Straube A (1998) Effects of the serotonin1B/1D receptor agonist zolmitriptan on motor cortical excitability in humans. Neurology 51:896–898

    CAS  PubMed  Google Scholar 

  • Whale R, Quested DJ, Laver D, Harrison PJ, Cowen PJ (2000) Serotonin transporter (5-HTT) promoter genotype may influence the prolactin response to clomipramine. Psychopharmacology 150:120–122

    Google Scholar 

  • Ziemann U, Hallett M (2000) Basic neurophysiological studies with TMS. In: George MS, Belmaker RH (eds) Transcranial magnetic stimulation in neuropsychiatry. American Psychiatric Press, Washington, D.C., pp 45–98

  • Ziemann U, Tergau F, Bruns D, Baudewig J, Paulus W (1997) Changes in human motor cortex excitability induced by dopaminergic and anti-dopaminergic drugs. Electroencephalogr Clin Neurophysiol 105:430–437

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry and Psychotherapy, University of Regensburg, Universitaetsstrasse 84, 93053, Regensburg, Germany

    Peter Eichhammer, Berthold Langguth, Rainer Wiegand, Alexander Kharraz, Ulrich Frick & Göran Hajak

Authors
  1. Peter Eichhammer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Berthold Langguth
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Rainer Wiegand
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Alexander Kharraz
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ulrich Frick
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Göran Hajak
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Peter Eichhammer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Eichhammer, P., Langguth, B., Wiegand, R. et al. Allelic variation in the serotonin transporter promoter affects neuromodulatory effects of a selective serotonin transporter reuptake inhibitor (SSRI). Psychopharmacology 166, 294–297 (2003). https://doi.org/10.1007/s00213-002-1370-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00213-002-1370-1

Keywords

Search

Navigation